Hypertension in patients with chronic kidney disease

Current Hypertension Reports

Volumn 11, Issue 5, 2009, Pages 329-336

  Chanda, Ranjan ^a   Fenves, Andrew Z ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; RENIN INHIBITOR; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ARTERIAL STIFFNESS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG FATALITY; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTENSIVE NEPHROSCLEROSIS; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MICROALBUMINURIA; NEPHROSCLEROSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEINURIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; UNITED STATES;

EID: 70349678612     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0056-z     Document Type: Review

References (50)

1. Levey AS, Coresh J, Greene T, et al.; Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145:247-254.
2. Kidney Disease Outcomes Quality Initiative Work Group: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(Suppl 1):S1-S290.
3. Ridao N, Luno J, Garcia de Vinuesa S, et al.: Prevalence of hypertension in renal disease. Nephrol Dial Transplant 2001, 16(Suppl 1):70-73.
4. Wang W, Lee ET, Fabsitz RR, et al.: A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: The Strong Heart Study. Hypertension 2006, 47:403-409.
5. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
6. Perneger TV, Nieto FJ, Whelton PK, et al.: A prospective study of blood pressure and serum creatinine. Results from the "Clue" study and the ARIC study. JAMA 1993, 269:488-493.
7. Fliser D, Franek E, Joest M, et al.: Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int 1997, 51:1196-1204.
8. Peterson JC, Adler S, Burkart JM, et al., for the MDRD Study Group: Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754-762.
9. Mallamaci F, Zuccala A, Zoccali C, et al.: The deletion polymorphism of the angiotensin-converting enzyme is associated with nephroangiosclerosis. Am J Hypertens 2000, 13:433-437.
10. Appel LJ, Wright JT Jr, Greene T, et al.; African American Study of Kidney Disease and Hypertension Collaborative Research Group: Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008, 168:832-839.
11. Wright JT Jr, Bakris G, Greene T, et al.; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002, 288:2421-2431.
12. Kopp JB, Smith MW, Nelson GW, et al.: MYH9 is a majoreffect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
13. Kao WH, Klag MJ, Meoni LA, et al.; Family Investigation of Nephropathy and Diabetes Research Group: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40:1185-1192.
14. Freedman BI, Sedor JR: HypertensioP-associated kidney disease: perhaps no more. J Am Soc Nephrol 2008, 19:2047-2051.
15. De Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004, 65:2309-2320.
16. Ruggenenti P, Perna A, Loriga G, et al.: Blood pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multi-centre, randomised controlled trial. Lancet 2005, 365:939-946.
17. Jafar TH, Stark PC, Schmid CH, et al.: Progression of kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 2003, 139:244-252.
18. Hou F, Xie D, Zhang X, et al.: Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007, 18:1889-1898.
19. Arici M, Erdem Y: Dual blockade of the renin-angiotensin system for cardiorenal protection: An update. Am J Kidney Dis 2009, 53:332-345.
20. Kunz R, FEiedrich C, Wolbers M, et al.: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30-48.
21. Catapano F, Chiodini P, De Nicola L, et al.: Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression. Am J Kidney Dis 2008, 52:475-485.
22. Bakris GL, Ruilope L, Locatelli F, et al.: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int 2007, 72:879-885.
23. Menne J, Farsang C, Deak L, et al.: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: The VALERIA trial. J Hypertens 2008, 26:1860-1867.
24. Mann JFE, Schmieder R, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
25. Navaneethan S, Nigwekar S, Sehgal A, et al.: Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. J Am Soc Nephrol 2009, 4:542-551.
26. Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
27. Parving HH, Brenner BM, McMurray JJ, et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 2009, 24:1663-1671.
28. Bakris GL, Weir MR, Secic M, et al.: Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int 2004, 65:1991-2002.
29. Horl MP, Horl WH: Hemodialysis-asPociated hyper tension: pathophysiology and therapy. Am J Kidney Dis 2002, 39:227-244.
30. Kamata T, Hishida A, Takita T, et al.: Morphologic abnormalities in the brain of chronically hemodialyzed patients without cerebrovascular disease. Am J Nephrol 2000, 20:27-31.
31. Iseki K, Nakai S, Shinzato T, et al.: Prevalence and determinants of hypertension in chronic hemodialysis patients in Japan. Ther Apher Dial 2007, 11:183-188.
32. Davenport A, Cox C, Thuraisingham R: Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008, 73:759-764.
33. Alborzi P, Patel N, Agarwal R: Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007, 2:1228-1238.
34. Agarwal R, Anderson MJ, Light RP: Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 2008, 28:210-217.
35. Agarwal R, Light RP: Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients. Am J Physiol Renal Physiol 2008, 294:F303-F308.
36. Agarwal R: Antihypertensive agents and artRrial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient. Curr Opin Nephrol Hypertens 2007, 16:409-415.
37. Inrig JK, Oddone EZ, Hasselblad V, et al.: Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 2007, 71:454-461.
38. Li Z, Lacson E Jr, Lowrie EG, et al.: The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006, 48:606-615.
39. Zheng S, Nath V, Coyne DW: ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. Am J Nephrol 2007, 27:522-529.
40. Kasiske BL, Anjum S, Shah R, et al.: Hypertension after kidney transplantation. Am J Kidney Dis 2004, 43:1071-1081.
41. Guidi E, Menghetti D, Milani S, et al.: Hypertension may be transplanted with the kidney in humans: A long-term historical prospective follow-up of recipients grafted with kidneys coming from donors with or without hypertension in their families. J Am Soc Nephrol 1996, 8:1131-1138.
42. Audard V, Matignon M, Hemery F, et al.: Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant 2006, 6:95-99.
43. Hiremath S, Fergusson D, Doucette S: Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence. Am J Transplant 2007, 7:2350-2360.
44. Bruno S, Remuzzi G, Ruggenenti P: Transplant renal artery stenosis. J Am Soc Nephrol 2004, 15:134-141.
45. Chapman AB, Johnson A, Gabow PA, et al.: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990, 323:1091-1096.
46. Oflaz H, Alisir S, Buyukaydin B, et al.: Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 2005, 68:2244-2249.
47. Jafar TH, Stark PC, Schmid CH, et al.: The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005, 67:265-271.
48. Schrier R, McFann K, Johnson A, et al.: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 2002, 13:1733-1739.
49. Kidney Disease Outcomes Quality Initiative Work Group: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. Am J Kidney Dis 2004, 43(Suppl 1):S16-S33.
50. Kidney Disease Outcomes Quality Initiative Work Group: K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45:S49-S57.